BSX · Boston Scientific Corp · Webcasts, Transcripts & Audio
$44.34
+0.14 (+0.32%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$64.27B
Shares
1.45B
Volume · Nov 13
9.7M
Avg daily vol (3M)
19.61M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Boston Scientific Corp Webcasts
Earnings calls, investor updates, investor days and conferences for Boston Scientific Corp (BSX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-11
Boston Scientific Corp (BSX) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-28
Boston Scientific Corp (BSX) Q3 2026 Earnings Call Transcript
Cautious tone
2027 downturn and recovery outlook
Product pipeline and launch timing
Penumbra acquisition
Revenue
$5.14B
▲ 1.4% YoY Diluted EPS
$0.40
▼ 21.6% YoY Gross margin
66.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-10
Boston Scientific Corp (BSX) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-29
Boston Scientific Corp (BSX) Q2 2026 Earnings Call Transcript
Cautious tone
Watchman/LAAC Market Slowdown
Penumbra Acquisition
Neuromodulation Growth
Revenue
$5.44B
▲ 7.5% YoY Diluted EPS
$0.61
▲ 15.1% YoY Gross margin
70.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-27
Boston Scientific Corp (BSX) May 27, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-22
Boston Scientific Corp (BSX) Q1 2026 Earnings Call Transcript
Cautious tone
WATCHMAN and PFA momentum
Urology and sacral neuromodulation
Penumbra acquisition and capital allocation
Revenue
$5.20B
▲ 11.6% YoY Diluted EPS
$0.90
▲ 100% YoY Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-03-28
Boston Scientific Corp (BSX) March 28, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-04
Boston Scientific Corp (BSX) Q4 2025 Earnings Call Transcript
Confident tone
WATCHMAN & Structural Heart
M&A and Pending Acquisitions
Regional Growth (U.S., Europe, Asia Pac)
Revenue
$5.29B*
▲ 15.8% YoY Gross margin
69.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-22
Boston Scientific Corp (BSX) Q3 2025 Earnings Call Transcript
Confident tone
EP / FARAPULSE momentum and ASCs
Quarterly financial outperformance
M&A and portfolio expansion
Revenue
$5.07B
▲ 20.3% YoY Diluted EPS
$0.51
▲ 59.4% YoY Gross margin
69.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-23
Boston Scientific Corp (BSX) Q2 2025 Earnings Call Transcript
Confident tone
Concomitant Procedures and EP Portfolio
Cardiovascular and Cardiology Growth
Regional Performance (U.S., EMEA, Asia Pacific)
Revenue
$5.06B
▲ 22.8% YoY Diluted EPS
$0.53
▲ 140.9% YoY Gross margin
67.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Boston Scientific Corp (BSX) Q1 2025 Earnings Call Transcript
Confident tone
Tariffs and tax/Pillar 2 outlook
FARAPULSE and EP franchise
Manufacturing footprint and U.S. investment
Revenue
$4.66B
▲ 20.9% YoY Diluted EPS
$0.45
▲ 36.4% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-05
Boston Scientific Corp (BSX) Q4 2024 Earnings Call Transcript
Confident tone
2025 financial guidance and outlook
China and VBP pricing pressures
Farapulse / EP franchise momentum
Revenue
$4.56B*
▲ 22.5% YoY Gross margin
67.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-23
Boston Scientific Corp (BSX) Q3 2024 Earnings Call Transcript
Confident tone
FARAPULSE PFA and AF Solutions
WATCHMAN Franchise
China and Asia Pacific Dynamics
Revenue
$4.21B
▲ 19.3% YoY Diluted EPS
$0.32
▼ 5.9% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-24
Boston Scientific Corp (BSX) Q2 2024 Earnings Call Transcript
Confident tone
FARAPULSE and EP Growth
Product Launches and Pipeline
M&A and Pending Acquisitions
Revenue
$4.12B
▲ 14.5% YoY Diluted EPS
$0.22
▲ 22.2% YoY Gross margin
69.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Boston Scientific Corp (BSX) Q1 2024 Earnings Call Transcript
Confident tone
FARAPULSE launch and EP momentum
Organic revenue growth and raised guidance
Gross margin pressure and inventory charges
Revenue
$3.86B
▲ 13.8% YoY Diluted EPS
$0.33
▲ 57.1% YoY Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-31
Boston Scientific Corp (BSX) Q4 2023 Earnings Call Transcript
Confident tone
2024 guidance and outlook
Product launches and pipeline
Gross margin and margin expansion
Revenue
$3.73B*
▲ 14.9% YoY Gross margin
69.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Boston Scientific Corp (BSX) Q3 2023 Earnings Call Transcript
Revenue
$3.53B
▲ 11.3% YoY Diluted EPS
$0.34
▲ 183.3% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
Boston Scientific Corp (BSX) Q2 2023 Earnings Call Transcript
Revenue
$3.60B
▲ 10.9% YoY Diluted EPS
$0.18
▲ 5.9% YoY Gross margin
70.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Boston Scientific Corp (BSX) Q1 2023 Earnings Call Transcript
Revenue
$3.39B
▲ 12% YoY Diluted EPS
$0.21
▲ 200% YoY Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-01
Boston Scientific Corp (BSX) Q4 2022 Earnings Call Transcript
Revenue
$3.24B*
▲ 3.7% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Boston Scientific Corp (BSX) Q3 2022 Earnings Call Transcript
Revenue
$3.17B
▲ 8.1% YoY Diluted EPS
$0.12
▼ 57.1% YoY Gross margin
69.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Boston Scientific Corp (BSX) Q2 2022 Earnings Call Transcript
Revenue
$3.24B
▲ 5.4% YoY Diluted EPS
$0.17
▲ 41.7% YoY Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Boston Scientific Corp (BSX) Q1 2022 Earnings Call Transcript
Revenue
$3.03B
▲ 10% YoY Diluted EPS
$0.07
▼ 69.6% YoY Gross margin
68.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-02
Boston Scientific Corp (BSX) Q4 2021 Earnings Call Transcript
Revenue
$3.13B*
▲ 15.5% YoY Gross margin
68.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Boston Scientific Corp (BSX) Q3 2021 Earnings Call Transcript
Revenue
$2.93B
▲ 10.3% YoY Diluted EPS
$0.28
Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-27
Boston Scientific Corp (BSX) Q2 2021 Earnings Call Transcript
Revenue
$3.08B
▲ 53.6% YoY Diluted EPS
$0.12
Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Boston Scientific Corp (BSX) Q1 2021 Earnings Call Transcript
Revenue
$2.75B
▲ 8.2% YoY Diluted EPS
$0.23
▲ 2200% YoY Gross margin
67.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Boston Scientific Corp (BSX) Q4 2020 Earnings Call Transcript
Revenue
$2.71B*
▼ 6.7% YoY Gross margin
63.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-28
Boston Scientific Corp (BSX) Q3 2020 Earnings Call Transcript
Revenue
$2.66B
▼ 1.8% YoY Diluted EPS
$-0.12
▼ 233.3% YoY Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-29
Boston Scientific Corp (BSX) Q2 2020 Earnings Call Transcript
Revenue
$2.00B
▼ 23.9% YoY Diluted EPS
$-0.11
▼ 200% YoY Gross margin
60.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Boston Scientific Corp (BSX) Q1 2020 Earnings Call Transcript
Revenue
$2.54B
▲ 2% YoY Diluted EPS
$0.01
▼ 96.7% YoY Gross margin
68.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-14
Boston Scientific Corp (BSX) Q4 2019 Earnings Call
Revenue
$2.90B*
▲ 13.4% YoY Gross margin
70.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 webcasts
Key facts
CIK
885725
CUSIP
101137107
13F (30d)
1217 filings
1128 filers
Visit website
Investor relations